Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | DDO | Q99489 | 1/20 | 0.50 |
| ▸ | IL4I1 | Q96RQ9 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263927 | 0.79 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL31154599 | 0.79 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL8873594 | 0.77 | KDM4E (0.58) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL9293635 | 0.77 | KDM4E (0.58) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL17618004 | 0.77 | KDM4E (0.58) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL6402311 | 0.77 | DAO (0.59) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL30162531 | 0.77 | KDM4E (0.58) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL6472543 | 0.76 | MAPK1 (0.47) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| Hydrochloric Acid SCHEMBL17601025 | 0.76 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL28431176 | 0.75 | BRD4 (0.53) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10139406-B2 | Alkyl quinolones as biomarkers of pseudomonas aeruginosa infection and uses thereof | THE UNIVERSITY OF NOTTINGHAM (GB) | 2018-11-27 | — | — | US | claimed |
| EP-2997382-B1 | ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF | UNIV NOTTINGHAM (GB) | 2018-07-11 | — | — | EP | claimed |
| US-20160131648-A1 | ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF | THE UNIVERSITY OF NOTTINGHAM (GB) | 2016-05-12 | — | — | US | claimed |
| EP-2997382-A1 | ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF | The University Of Nottingham (GB) | 2016-03-23 | — | — | EP | claimed |
| WO-2014184535-A1 | ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF | THE UNIVERSITY OF NOTTINGHAM (GB) | 2014-11-20 | — | — | WO | claimed |
| WO-2021022066-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BACTERIAL VIRULENCE AND FLIM-BASED DEVICE AND METHOD FOR ANTIBIOTIC SUSCEPTIBILITY TESTING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-04 | — | — | WO | disclosed |
| US-10139406-B2 | Alkyl quinolones as biomarkers of pseudomonas aeruginosa infection and uses thereof | THE UNIVERSITY OF NOTTINGHAM (GB) | 2018-11-27 | — | — | US | disclosed |
| US-10139406-B2 | Alkyl quinolones as biomarkers of pseudomonas aeruginosa infection and uses thereof | THE UNIVERSITY OF NOTTINGHAM (GB) | 2018-11-27 | — | — | US | disclosed |
| US-10139406-B2 | Alkyl quinolones as biomarkers of pseudomonas aeruginosa infection and uses thereof | THE UNIVERSITY OF NOTTINGHAM (GB) | 2018-11-27 | — | — | US | disclosed |
| EP-2997382-B1 | ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF | UNIV NOTTINGHAM (GB) | 2018-07-11 | — | — | EP | disclosed |
| EP-2997382-B1 | ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF | UNIV NOTTINGHAM (GB) | 2018-07-11 | — | — | EP | disclosed |
| US-20160131648-A1 | ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF | THE UNIVERSITY OF NOTTINGHAM (GB) | 2016-05-12 | — | — | US | disclosed |
| US-6964973-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-11-15 | — | — | US | disclosed |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6566372-B1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer | LIGAND PHARMACEUTICALS INCORPORATED | 2003-05-20 | — | — | US | disclosed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
| US-4049811-A | MICROBIOCIDES | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1977-09-20 | — | — | US | disclosed |
| US-3988460-A | Cyclopentenoquinolone compounds for treating bacterial infections | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-10-26 | — | — | US | disclosed |
| US-3966743-A | ANTIMICROBIAL | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160131648-A1 | ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF | NQO2, QARS1, CD14 | KDM4E 4049/4885ALDH1A1 1222/4885HPGD 126/4885 |
| US-10139406-B2 | Alkyl quinolones as biomarkers of pseudomonas aeruginosa infection and uses thereof | NQO2, QARS1, CD14 | KDM4E 4049/4885ALDH1A1 1222/4885HPGD 126/4885 |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | KDM4E 2209/4885ALDH1A1 2131/4885HPGD 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.